By a News Reporter-Staff News Editor at Biotech Business Week -- Data detailed on Gram-Positive Bacteria have been presented. According to news reporting originating from London, Canada, by NewsRx correspondents, research stated, "Bacteriocin-producing probiotic Streptococcus salivarius M18 offers beneficial modulatory capabilities within the oral microbiome, apparently through potent inhibitory activity against potentially deleterious bacteria, such as Streptococcus pyogenes. The oral cavity persistence of S. salivarius M18 was investigated in 75 subjects receiving four different doses for 28 days."
Our news editors obtained a quote from the research from Lawson Health Research Institute, "Sixty per cent of the subjects already had some inhibitor-producing S. salivarius in their saliva prior to probiotic intervention. Strain M18's persistence was dependent upon the dose, but not the period of administration. Culture analysis indicated that in some individuals the introduced strain had almost entirely replaced the indigenous S. salivarius, though the total numbers of the species did not increase. Selected subjects showing either high or low probiotic persistence had their salivary populations profiled using Illumina sequencing of the V6 region of the 16S rRNA gene. Analysis indicated that while certain bacterial phenotypes were markedly modulated, the overall composition of the oral microbiome was not modified by the probiotic treatment. Megaplasmids encoding bacteriocins and adhesion factors were transferred in vitro to generate a transconjugant S. salivarius exhibiting enhanced antimicrobial production and binding capabilities to HEp-2 cells. Since no widespread perturbation of the existing indigenous microbiota was associated with oral instillation and given its antimicrobial activity against potentially pathogenic streptococci, it appears that application of probiotic strain M18 offers potential low impact alternative to classical antibiotic prophylaxis."
According to the news editors, the research concluded: "For candidate probiotic strains having relatively poor antimicrobial or adhesive properties, unique derivatives displaying improved probiotic performance may be engineered in vitro by megaplasmid transfer."
For more information on this research see: Persistence of the oral probiotic Streptococcus salivarius M18 is dose dependent and megaplasmid transfer can augment their bacteriocin production and adhesion characteristics. Plos One, 2013;8(6):e65991. (Public Library of Science - www.plos.org; Plos One - www.plosone.org)
The news editors report that additional information may be obtained by contacting J.P. Burton, Canadian Research and Development Centre for Probiotics, Lawson Health Research Institute, London, Ontario, Canada. Additional authors for this research include P.A. Wescombe, J.M. Macklaim, M.H. Chai, K. Macdonald, J.D. Hale, J. Tagg, G. Reid, G.B. Gloor and P.A Cadieux (see also Gram-Positive Bacteria).
Keywords for this news article include: London, Canada, Ontario, Bacteriocins, Streptococcus, Streptococcaceae, Bacterial Proteins, Gram Positive Cocci, Gram-Positive Bacteria, North and Central America, Pore Forming Cytotoxic Proteins.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC